Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Sandborn WJ, et al. Among authors: colombel jf. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451663 Clinical Trial.
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.
Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P; BMBF Competence Network "Inflammatory Bowel disease". Schreiber S, et al. Among authors: colombel jf. Int J Colorectal Dis. 2001 Feb;16(1):1-11; discussion 12-3. doi: 10.1007/s003840100285. Int J Colorectal Dis. 2001. PMID: 11317691
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR. Sandborn WJ, et al. Among authors: colombel jf. Inflamm Bowel Dis. 2001 Aug;7(3):192-201. doi: 10.1097/00054725-200108000-00003. Inflamm Bowel Dis. 2001. PMID: 11515844
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Among authors: colombel jf. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.
Management of Crohn's disease of the ileoanal pouch with infliximab.
Colombel JF, Ricart E, Loftus EV Jr, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Colombel JF, et al. Am J Gastroenterol. 2003 Oct;98(10):2239-44. doi: 10.1111/j.1572-0241.2003.07675.x. Am J Gastroenterol. 2003. PMID: 14572574
Environmental factors in familial Crohn's disease in Belgium.
Van Kruiningen HJ, Joossens M, Vermeire S, Joossens S, Debeugny S, Gower-Rousseau C, Cortot A, Colombel JF, Rutgeerts P, Vlietinck R. Van Kruiningen HJ, et al. Among authors: colombel jf. Inflamm Bowel Dis. 2005 Apr;11(4):360-5. doi: 10.1097/01.mib.0000158536.31557.90. Inflamm Bowel Dis. 2005. PMID: 15803025
1,162 results